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Improved sleep in military personnel
is associated with changes in the
expression of inflammatory genes
and improvement in depression
symptoms
Whitney S. Livingston 1*, Heather L. Rusch 1, Paula V. Nersesian 1,2, Tristin Baxter 3,
Vincent Mysliwiec 3 and Jessica M. Gill 1
1 National Institutes of Nursing Research, National Institutes of Health, Bethesda, MD, USA, 2 Johns Hopkins University
School of Nursing, Baltimore, MD, USA, 3 Madigan Army Medical Center, Tacoma, WA, USA
Study objectives: Sleep disturbances are common in military personnel and are
associated with increased risk for psychiatric morbidity, including posttraumatic stress
disorder (PTSD) and depression, as well as inflammation. Improved sleep quality is linked
to reductions in inflammatory bio-markers; however, the underlying mechanisms remain
elusive.
Methods: In this study, we examine whole genome expression changes related to
improved sleep in 68 military personnel diagnosed with insomnia. Subjects were classified
into the following groups and then compared: improved sleep (n=46), or non-improved
sleep (n=22) following three months of standard of care treatment for insomnia. Within
subject differential expression was determined from microarray data using the Partek
Genomics Suite analysis program and the ingenuity pathway analysis (IPA) was used
to determine key regulators of observed expression changes. Changes in symptoms of
depression and PTSD were also compared.
Results: At baseline, both groups were similar in demographics, clinical characteristics,
and gene-expression profiles. The microarray data revealed that 217 coding genes were
differentially expressed at the follow-up-period compared to baseline in the participants
with improved sleep. Expression of inflammatory cytokines were reduced including IL-
1β, IL-6, IL-8, and IL-13, with fold changes ranging from  3.19 to  2.1, and there were
increases in the expression of inflammatory regulatory genes including toll-like receptors
1, 4, 7, and 8 in the improved sleep group. IPA revealed six gene networks, including
ubiquitin, which was a major regulator in these gene-expression changes. The improved
sleep group also had a significant reduction in the severity of depressive symptoms.
Conclusion: Interventions that restore sleep likely reduce the expression of inflam-
matory genes, which relate to ubiquitin genes and relate to reductions in depressive
symptoms.
Keywords: gene expression, insomnia, inflammation, depression, military personnel
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Introduction
Military personnel are often exposed to stressful conditions and
erratic sleep schedules during deployment, thereby increasing
their risk of developing a sleep disorder,most notably insomnia (1,
2). Deployment also increases the risk for psychiatric morbidity,
including symptoms of posttraumatic stress disorder (PTSD) and
depression, which are often comorbid with insomnia (1, 3–5).
Insomnia is the most common symptom for referral in military
personnel returning from deployment in Operation Enduring
Freedom and Operation Iraqi Freedom (3). Not only is insomnia
common but it also results in substantial costs to the individual
and society. In the United States, total costs in productivity loss
for chronic insomnia (e.g., employment disruption, insomnia-
related accidents) are estimated to be between $77 and $92million
each year (6) and total annual costs are estimated to be beyond
$100 billion (7). In addition, more than half of military personnel
with sleep disturbances present with at least one other medical
comorbidity, and those with insomnia are two times more likely
to have PTSD (8). Therefore, there is a complex interplay between
sleep quality and maintenance of physical and psychiatric health
in military personnel, which likely has underlying biological
foundations.
Recent studies have begun to determine the relationship of
sleep to psychiatric morbidity in those who are under extreme
stress (9). For example, pre-deployment sleep disturbance is
linked to the onset of depression and PTSD following deploy-
ment (10). PTSD includes the symptom of nightmares, which
is highly related to insomnia onset and non-remittance (11).
Depression also includes symptoms of insomnia including diffi-
culty falling or staying asleep, and these sleep disturbances often
do not remit with standard of care treatment for depression
(12). Therefore, current studies suggest that there is a shared
vulnerability among PTSD, depression, and insomnia, and that
these symptoms are often highly related in military personnel
who deploy. Seeking care for sleep is often less stigmatizing than
mental health care, resulting in military personnel seeking care
for insomnia at almost five times the rate as mental health care
(13, 14). Therefore, a better understanding of the underlying
shared vulnerability of PTSD, depression and insomnia symptoms
following deployment may inform interventions to address these
comorbidities.
Sleep disturbance, PTSD, and depression are all associated
with higher concentrations of inflammatory bio-markers, as well
as a greater risk for inflammatory-related morbidities including:
metabolic syndrome, cardiovascular disease, obesity, and type II
Abbreviations: BMI, body mass index; CBT, cognitive behavioral therapy; CCL4,
chemokine (C–C motif) ligand 4; CRP, C-reactive protein; CTNNβ1, catenin
(cadherin-associated protein), beta 1, 88 kDa; FDR, false discovery rate; GC,
GeneChip; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-8, interleukin 8; IL-
13, interleukin 13; IPA, ingenuity pathway analysis; NFATC2, nuclear factor of
activated T-cells; OSA, obstructive sleep apnea; PCL-M, posttraumatic stress dis-
order checklist-military version; PDK4, pyruvate dehydrogenase kinase, isozyme 4;
PKS, polyketide synthase; PSQI, the Pittsburg sleep quality index; PTSD, posttrau-
matic stress disorder; QIDS, quick inventory of depressive symptomatology; REML,
restricted maximum likelihood; RIN, RNA integrity numbers; RMA, robust multi-
array average; TLR1, toll-like receptor 1; TLR4, toll-like receptor 4; TLR7, toll-like
receptor 7; TLR8, toll-like receptor 8; TNF, tumor necrosis factor; UBC, ubiquitin.
diabetes (15–17). Even short-term reductions in sleep duration in
healthy participants increases inflammatory cytokine production,
including interleukin-6 (IL-6) (18–20). Chronic insomnia (21),
as well as PTSD and depression are associated with increased
concentrations of inflammatory cytokines (22). We previously
reported that PTSD, depression, and insomnia in military per-
sonnel are associated with higher concentrations of inflamma-
tory proteins including C-reactive protein (CRP) (23), and that
improved sleep resulted in reductions in inflammation (24).
Although these findings support the relationship between sleep
and inflammation, the underlying molecular mechanisms of
changes in inflammation following sleep improvement remain
elusive (2). Gene-expression changes lead to differential pro-
tein activity in general; however, there are many other mecha-
nisms that can contribute to the regulation of protein produc-
tion, and availability, including epigenetic modifications. There-
fore, gene-expression changes are one of the first investigations
that can explain molecular mechanisms related to proteomic
activity changes, and provide novel insights into complex inter-
relationships among gene-regulatory mechanisms.
Examination of gene-expression profiles provides insight into
how altered gene-activity relates to stress exposure and symptoms.
Expression of a gene can increase or decrease and is the initial step
to producing proteins that communicate cell function changes,
including those active in the immune response system. Combat-
related stressors, such as irregular work schedules, traumatic brain
injuries, and other life threatening events, are linked to greater
concentrations of inflammatory proteins, which are likely a result
of gene-expression changes (25). Peripheral blood gene expression
is comparable to post-mortem expression in more than 60% of
genes, providing a minimally invasive method to investigate gene
expression changes in living individuals (26, 27). Peripheral blood
has been used to determine that reductions in the expression of
circadian rhythm genes, including Clock, brain and muscle Arnt-
like protein 1, and Period1, are implicated in symptoms of depres-
sion (28). PTSD is also linked to altered gene expression, including
reductions in the expression of immune-regulating genes (29);
however, the role of sleep and depression were not determined.
Identification of inflammatory gene-expression changes related to
sleep disturbance might allow for an understanding of the impact
of insomnia on other systems andmay inform development of tar-
geted interventions to help prevent the development of comorbid
disorders and inflammation.
To investigate this critical issue, we used an observational
study of military personnel following deployment to determine
global gene-expression changes related to improved sleep follow-
ing 3months of standard of care treatment. These findings may
provide the insight needed to understand relationships between
sleep, gene regulation of inflammation, and mental health.
Materials and Methods
Study Design
This investigation is part of a large ongoing study of U.S. military
personnel attending for an initial evaluation of sleep disturbance
at the Madigan Army Medical Center Sleep Medicine Clinic in
Tacoma, WA, USA. The institutional review board at Madigan
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Army Medical Center approved the study, and informed con-
sent was obtained from each participant (5). Sixty-eight partici-
pants met the study’s inclusion criteria for a sleep diagnosis and
completed both pre- and post-treatment assessments; they are
included in this analysis. Study participants whomet the inclusion
criteria were active-duty military personnel who deployed within
the previous 18months with a current diagnosis of insomnia or
comorbid insomnia with obstructive sleep apnea (OSA), as pre-
viously described (5). Participants were excluded from the study
if they had a recent history of drug or alcohol abuse or current
diagnosis of bipolar disorder, schizophrenia, or other psychotic
disorder. Symptoms related to sleep quality, depression, and PTSD
were evaluated through validated instruments at pre-treatment
and post-treatment. Participants were classified into one of two
groups (improved sleep or non-improved sleep) based on changes
in sleep quality from pre- to post-treatment. Both groups were
compared on gene-expression changes in inflammatory genes, as
well as changes in symptoms of PTSD and depression.
Assessment and Treatment of Insomnia and OSA
All participants underwent a clinical evaluation and overnight
polysomnography as part of a sleep medicine evaluation using
standardized techniques previously reported (5). Depending on
their sleep disorder diagnosis, patients were then assigned to
a standard of care treatment group. Those with an insomnia
diagnosis received 3months of sleep-focused cognitive behavioral
treatment for insomnia (CBT-i), which included aspects of cog-
nitive therapy, stimulus control, sleep restriction, sleep practice
(hygiene) education, and time monitoring behavior. Participants
diagnosedwith comorbid insomnia andOSA received either sleep
education or 3months of CBT-i for their insomnia, and autoti-
trating positive airway pressure therapy (APAP) for their OSA.
A psychologist certified in behavioral sleep medicine or a sleep
medicine physician with expertise in CBT-I administered and
oversaw all treatments.
Defining Improved Sleep
The Pittsburgh sleep quality index (PSQI) was administered to
assess participants’ sleep quality and sleep dysfunction over the
previous month. This self-report questionnaire has strong diag-
nostic sensitivity in differentiating good and poor sleepers. Based
on a scale of 0 (healthy sleep quality) to 21 (unhealthy sleep
quality), a cut-off score of more than 5 is consistent with an
insomnia diagnosis (30) and is both reliable (Cronbach’sα= 0.83)
and valid (κ= 0.75, p< 0.001). For analysis purposes, participants
with a reduction in their PSQI score from pre- to post-treatment
were assigned to the improved sleep group (n= 46). Meanwhile,
participants with an increase or no change in PSQI score frompre-
to post-treatment were assigned to the non-improved sleep group
(n= 22).
Assessment of PTSD and Depression
Symptoms of depressionweremeasured using the quick inventory
of depressive symptomatology (QIDS). This 16-item inventory
has a total possible score range from 0 (lowest severity) to 27
(highest severity). A score of 11, which indicates a moderate
severity of depression, was used as the diagnosis cut-off (31). The
PTSD checklist-military version (PCL-M) was used to determine
symptoms of PTSD (32). A total possible score ranges from 17
(lowest severity) to 85 (highest severity). A total score of 50 and
above resulted in a positive PTSD diagnostic screen. The PCL
is both reliable and valid compared to the gold standard of the
Structured Clinical Interview for DSM-III-R (33).
mRNA Acquisition, Quantitation, and
Hybridization
Blood samples were collected in PAXgene blood RNA tubes
and processed with PAXgene™ Blood RNA Kits (PreAnalytiX,
Qiagen) for RNA extraction. Quality and quantity of extracted
RNA were evaluated with the NanoDrop DN-1000 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE, USA) and
the Agilent Bioanalyzer 2100 eukaryotic total RNA Nano assay
(Agilent Technologies, Inc., Santa Clara, CA, USA). The 260/280
ratio ranged from 2.03 to 2.34 and the RNA integrity num-
bers (RIN) were >7.0 in all samples. According to standards
(34) a RIN of 6.0 or greater is indicative of admissible quality,
and no samples were excluded based on this criterion. Using
the GeneChip (GC) 30 IVT Plus Expression kit, each RNA
(100 ng) sample was reverse transcribed, converted to biotiny-
lated cRNA, and hybridized to Affymetrix HG-U133 Plus 2.0
microarrays (Affymetrix, Santa Clara, CA, USA), which con-
tain 54,675 probe-sets representing more than 38,500 specific
genes. After staining with streptavidin-phycoerythrin and thor-
ough washing, the raw data were obtained by laser scanning imag-
ing. All assays were undertaken based on standard Affymetrix
protocols.
Statistical Analysis
PartekGenomics Suite software, version 6.6 (Partek Inc., St. Louis,
MO, USA), was used for all analytic procedures performed on
microarray data. Interrogating probes were imported, and correc-
tions for background signal were applied using the robust multi-
array average (RMA)method, with additional corrections applied
for the GC-content of probes. The probe-sets were standardized
using quantile normalization, and expression levels of each probe
underwent log-2 transformation to yield distributions of data that
more closely approximated normality.
Parameters for identifying differentially expressed genes over
time were then identified using analysis of variance (ANOVA)
of each probe set’s expression level as a function of time: pre-
treatment compared to post-treatment while adjusting for batch
effect. A repeated measures comparison was made in each group.
Restricted maximum likelihood (REML) method was employed
to fit the fixed and random effects of the design separately. Sig-
nificant differentially expressed gene lists were generated based
on criteria of 1.5-fold (up or down) change magnitude and a p-
value corrected for multiple comparisons using a false discovery
rate (FDR)<0.05, for each group.
Two-tailed chi-square tests and independent t-tests were used
to investigate any pre-treatment group differences that might
affect the main analysis. Fisher’s exact tests were used when
expected cell counts were <5. The main analysis investigated the
relationship between sleep quality improvements or declines and
symptoms of PTSD and depression, and gene expression changes
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following 3months of sleep treatment. Separate paired t-tests
were used to examine changes in outcome variables from pre-
to post-treatment for both groups. Independent t-tests were used
to examine between-group differences on outcome variables. The
confidence level was set at p= 0.05 for all analyses.
QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN Red-
wood City, www.qiagen.com/ingenuity) was used to determine
which diseases and disorders related to observed gene-expression
changes, as well as top-gene networks implicated in these gene-
expression changes.
Results
Demographics and Clinical Characteristics
The demographic, military, and clinical characteristics of the 68
participants are described in Table 1. As a whole, the sample
was primarily male (97%) and Caucasian (62%) with a mean
age of 33.8 years (7.8 SD) and 13.8 years (1.8 SD) of educa-
tion. At pre-treatment, 47% of participants scored positive for
depression and 28% scored positive for PTSD. Current use of
relevant medications was reported by 40% of the participants.
They include antidepressants (28%), pain medications (18%),
benzodiazepines (6%), non-benzodiazepines (6%), and the alpha-
blocker, prazosin (4%). At pre-treatment, all participants reported
a score of at least six on the PSQI, which is a valid indica-
tion of poor sleep. There were no between-group differences in
demographic variables [i.e., age, gender, race, education, body
mass index (BMI), medication use, and military characteris-
tics] with the exception of military rank, for which higher
level ranks were more prevalent in the improved sleep group
(p= 0.015). The prevalence of insomnia, OSA, traumatic brain
injury (TBI), depression, and PTSD diagnoses were comparable
between groups at baseline and both groups were characterized
with high rates of these comorbid symptoms. There was no dif-
ference in treatment assignment, either CBT or APAP, between
the improved sleep and non-improved sleep groups. The mean
score in the PSQI was significantly different, with the improved
sleep group having amean score change of 4.8, whereas the non-
improved group had an increase of 2.8 on the PSQI, p< 0.01 (see
Table 2).
Psychological Symptom Change
Sleep quality, depression, and PTSD outcomes were assessed
before and after 3months of sleep treatment. Table 2 details the
pre- and post-treatment symptom severity of both groups. Briefly,
from pre- to post-treatment, the improved sleep group reported
significant reductions in depression [t(45)= 3.463, p= 0.001] and
a trend for decreases in posttraumatic symptoms [t(45)= 1.875,
p= 0.067]. These improvements were significant between groups
(all p-values <0.05). Meanwhile, the non-improved sleep group
reported no significant change in depression (p= 0.134) or post-
traumatic symptoms (p= 0.223).
Gene-Expression Profiles
The microarray data revealed that 217 coding genes (Table 3)
were differentially expressed at the follow-up-period compared to
baseline in the participants who improved in sleep. Of these 217
TABLE 1 | Demographic, military, and clinical characteristics.
Improved
sleep
(n= 46)
Non-improved
sleep
(n= 22)
x2/t p
Age: mean (SD) 33.5 (7.5) 34.3 (8.7) 0.358 0.722
Males: n (%) 45 (97.8) 21 (95.5) 0.293 0.546
Race: n (%) 3.663 0.056
Caucasian 32 (69.6) 10 (45.5)
All others 14 (30.4) 12 (54.5)
Education in years:
mean (SD)
14.0 (2.1) 13.4 (1.3)  1.202 0.234
Rank: n (%) 5.921 0.015
Lower 26 (56.5) 19 (86.4)
Senior or Officer 20 (43.5) 3 (13.6)
Front line military
exposure: n (%)
17 (37.0) 9 (40.9) 0.098 0.754
Number of
deployments: n (%)
0.718 0.397
1 or 2 30 (65.2) 12 (54.5)
3 or more 16 (34.8) 10 (45.5)
Time since
deployment: n (%)
0.729 0.393
<6months 14 (30.4) 9 (40.9)
>6months 32 (69.6) 13 (59.1)
BMI: mean (SD) 30.2 (4.3) 30.5 (3.4) 0.330 0.743
Medication use: n (%) 16 (34.8) 11 (50.0) 1.440 0.230
OSA diagnosis: n (%) 12 (26.1) 5 (22.7) 0.090 0.765
TBI diagnosis: n (%) 18 (39.1) 9 (40.9) 0.020 0.888
Probable depression
diagnosis: n (%)
21 (45.7) 11 (50.0) 0.113 0.737
Probable PTSD
diagnosis: n (%)
11 (23.9) 8 (36.4) 1.146 0.284
BMI, body mass index; OSA, obstructive sleep apnea; PTSD, posttraumatic stress
disorder; TBI, traumatic brain injury.
Fisher’s exact test was used when expected cell counts were <5.
genes, 113 genes were down-regulated (Table 4) and 104 were up-
regulated (Table 5). None of these genes changed significantly in
the non-improved sleep group.
Expression of inflammatory cytokines were substantially
reduced in the improved sleep group, including interleukin 1 beta
(IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interleukin
13 (IL-13), with fold changes ranging from  3.19 to  2.10. We
also report significant reductions in chemokine genes including
chemokine (C–C motif) ligand 4 (CCL4), which was the most
substantially reduced gene, with a fold change of 3.39, as well as
chemokine (C–C motif) ligand 3 (CCL3), and chemokine (C–C
motif) ligand 5 (CCL5), with fold-changes of  3.00 and  2.97,
respectively, in the improved sleep group.
Genes with increases in expression in the improved sleep group
were predominately inflammatory regulatory genes including toll-
like receptors 4 and 8 (TLR4 and TLR8), with a 2.66- and 2.62-
fold change, respectively, as well as toll-like receptors 7 and 1
(TLR7 and TLR1), with fold changes of 2.6 and 1.9, respectively.
Stress-related genes of cytochrome P450, family 1, subfamily B,
polypeptide 1 (CYP1B1), FKBP506 binding protein (FKBP506),
and FK506 binding protein 15, 133 kDa (FKBP15) exhibited fold
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TABLE 2 | Pre- and post-treatment symptom severity mean (SD).
Improved sleep (n=46) Non-improved sleep (n=22) Between-group
Pre-treatment Post-treatment p Pre-treatment Post-treatment p Baseline Changea
p p
Sleep quality 12.8 (4.1) 8.0 (3.9) <0.001 12.1 (3.6) 14.9 (3.1) <0.001 0.484 <0.001
Depression severity 10.5 (5.3) 8.1 (5.0) 0.001 11.00 (4.7) 12.2 (5.0) 0.134 0.732 0.002
PTSD severity 38.7 (15.3) 35.6 (16.5) 0.067 43.5 (16.2) 46.5 (17.6) 0.223 0.237 0.040
aPre- to post-treatment change-score. Bold font indicates findings with significant change.
changes >2.0. The pyruvate dehydrogenase kinase, isozyme 4
genes had the greatest increase in expression, with a fold change
of 3.12.
The IPA report shows conical pathways were altered and
related to improved sleep. The pathways include the inflammatory
response, infectious disease, inflammatory disease, and organis-
mal injury and abnormalities. There were six significant gene-
networks identified, the scores of which are reported in Table 6.
Networks 1 and 2 are provided in Figures 1 and 2, and the remain-
ing Figures S1–S4 are provided in the Supplementary Material.
With the exception of the third IPA network, the other five con-
tained genes above a fold change of 2 in the networks reported.
Network 1 includes genes related to cellular development and tis-
sue disorders, and has a score of 29. In this network, there are three
main hubs: Catenin (cadherin-associated protein), beta 1, 88 kDa
(CTNNβ1), toll-like receptors (TLR), and interleukin 2 (IL-2), as
well asminor hubs of ubiquitin (UBC), polyketide synthase (PKS),
and nuclear factor of activated T-cells 2 (NFATC2). Network 2
has a score of 23, and includes genes related to cancer, and tissue
and developmental disorders. This network has a primary hub of
UBC, which is related to an increase in expression of FKBP15 and
ATPase, H+ transporting, lysosomal 70 kDa, and V1 subunit A
(ATP6V1A), and reductions in the expression of TSEN54 tRNA
splicing endonuclease and megalencephalic leukoencephalopathy
with subcortical cysts 1.
Discussion
The primary aim of the current study is to examine the relation-
ship between changes in self-reported sleep quality and changes
in expression of inflammatory genes and symptoms of depres-
sion and PTSD following 3months of sleep treatment in mili-
tary personnel with insomnia and comorbid psychiatric disor-
ders. At post-treatment, participants with improved sleep have
significantly reduced depression symptoms and changes in gene
expression, which most notably reflect reductions in inflam-
matory cytokine genes. These novel findings provide unique
insights into our previous findings, which indicated improved
sleep quality is associated with reductions in concentrations of
CRP and improvements in health-related quality of life in mil-
itary personnel (23). These results suggest that sleep-focused
treatments effectively reduce inflammatory gene activity, and
may attenuate the risk for inflammatory-related morbidity in
this population.
Specifically, we report that gene activity is reduced in 113 genes
following improved sleep, including significant reductions in the
expression of the following inflammatory cytokine genes: CCL4,
IL-1β, tumor necrosis factor (TNF), IL-6, and IL-13 (Table 4). Ele-
vated concentrations of IL-6 have been associated with symptoms
of insomnia, PTSD, and depression (22, 35). The reduction in IL-
6 secretion has significant ramifications as IL-6 has a pertinent
role in the inflammatory response, including initiation of the
acute-phase response and increasing metabolic risks as well as
vascular plaque formation (36). Peripherally, IL-6 activates the
production of inflammatory cytokines by initiating intracellular
signaling with TLR (37). IL-6 is linked to substantial morbidity
risks through arterial plaque formation, which can lead to car-
diovascular disease and risks, high BMI, chronic pain, and an
elevated risk for diabetes (38–42). Therefore, our findings suggest
that improved sleep quality plays an important role in decreasing
inflammation through gene-expression networks, whichmay also
have a health-promoting role over time.
IL-6 also crosses the blood–brain barrier and contributes
to central inflammation, and higher activity can contribute to
mood alterations including symptoms of depression and anx-
iety (36). Here, we report depression symptoms decrease fol-
lowing improved sleep, and there is a trend for decreases in
PTSD symptoms. Prior studies link inflammation to the onset of
depressive symptoms, suggesting a complex bi-directional rela-
tionship that contributes to mental well-being (43, 44). Higher
concentrations of IL-6 as well as increased gene-activity are estab-
lished bio-markers for depression (45), yet, less is known about
the inflammatory mechanisms that result from the interaction
of insomnia and depression, and the resolution of symptoms.
Previously, we reported that depression and insomnia in mili-
tary personnel are associated with higher concentrations of CRP
(23), and that improved sleep reduces inflammation (24). Here,
we extend these findings by linking gene expression to sleep
improvement and reduction in depression symptoms. In addi-
tion, we report a significant reduction in the expression of the
CCL4 gene, which was reduced by  3.39 fold in the improved
sleep group. CCL4 is an initiator of the inflammatory processes,
suggesting inflammatory pathways are reduced in activity fol-
lowing sleep restoration and reduction in depression symptoms.
Greater CCL4 activity is linked to major depressive disorder in
both adolescents and adults (46, 47); however, it is not clear if
the activity of this gene or other inflammatory initiating genes
change following sleep improvement and mood change. There-
fore, our findings of reductions in CCL4 following sleep improve-
ment are novel and provide some initial insights into complex
relationships among genes that regulate inflammation, sleep, and
mood.
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TABLE 3 | All differentially expressed genes.
Gene symbol Gene title Fold-change p-Value
CCL4 Chemokine (C—C motif) ligand 4  3.38991 0.000400502
EGR3 Early growth response 3  3.33259 4.37E-05
IL1B Interleukin 1, beta  3.19348 0.00054254
TIGIT T cell immunoreceptor with Ig and ITIM domains  2.999421 0.000116146
CD96 CD96 molecule  2.9992104 0.000593266
CCL3///CCL3L1///CCL3L3 Chemokine (C—C motif) ligand 3///chemokine (C—C motif) ligand 3-like 1///chemokine  2.99786 1.32E-05
CCL5 Chemokine (C—C motif) ligand 5  2.96621 0.000882838
TNF Tumor necrosis factor  2.90578 0.000536776
DUSP1 Dual specificity phosphatase 1  2.89657 1.73E-05
GATA3 GATA binding protein 3  2.889336 0.000852941
PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)  2.86159 0.000116328
BZRAP1 Benzodiazepine receptor (peripheral) associated protein 1  2.84583 0.000429033
KIR3DL1///KIR3DL2///LOC727787 Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1///k  2.79571 0.00111701
IL18R1 Interleukin 18 receptor 1  2.79239 0.00131446
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  2.77617 0.000468791
IFITM1 Interferon Interferon-induced transmembrane protein 1 (9—27)  2.67642 0.000796847
IL6 Interleukin 6 (interferon, beta 2)  2.66587 0.000169597
IFITM1 Interferon Interferon-induced transmembrane protein 1 (9—27)  2.59115 0.00120357
GLCCI1 Glucocorticoid Glucocorticoid-induced transcript 1  2.57928 0.000863656
PER1 Period homolog 1 (Drosophila)  2.34547 0.000172781
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.31319 0.000858636
TARP TCR gamma alternate reading frame protein  2.2425 0.00123683
TP53INP2 Tumor protein p53 inducible nuclear protein 2  2.23152 2.18E-04
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae)  2.22332 0.00055414
ZNF831 Zinc finger protein 831  2.21191 0.000940436
BCL10 B-cell CLL/lymphoma 10  2.19636 1.92E-04
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.18635 0.00138229
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.17218 0.00136634
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor)  2.17143 2.79E-05
IL13 Interleukin 13  2.0998 0.000453301
ZNF831 Zinc finger protein 831  2.07393 0.000998177
GZMB Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)  2.07291 0.000106599
KLF12 Kruppel-like factor 12  2.06742 0.000474026
SPON2 Spondin 2, extracellular matrix protein  2.06256 0.000562071
MBNL2 Muscleblind-like 2 (Drosophila)  2.06215 0.000146908
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  2.04976 0.000826814
CRA Complement factor C4  2.04778987 7.09143E-05
FCAR Fc fragment of IgA, receptor for  2.03608 1.89E-04
NCL Nucleolin  2.0312 4.39101E-07
IFRD1 Interferon-related developmental regulator 1  2.02534 7.16E-06
S1PR5 Sphingosine-1-phosphate receptor 5  1.99987 0.000877998
NAP1L5 Nucleosome assembly protein 1-like 5  1.9825 0.00103436
FGFBP2 Fibroblast growth factor binding protein 2  1.95856 0.00097833
TRD@ T cell receptor delta locus  1.95283 0.00111344
PYHIN1 Pyrin and HIN domain family, member 1  1.93462 0.000986752
GFI1 Growth factor independent 1 transcription repressor  1.93194 0.00076425
GZMM Granzyme M (lymphocyte met-ase 1)  1.93125 0.00085383
TRD@ T cell receptor delta locus  1.9207 0.00111727
TSC22D3 TSC22 domain family, member 3  1.91096 2.28E-06
KLRB1 Killer cell lectin-like receptor subfamily B, member 1  1.90964 0.00136588
IL18RAP Interleukin 18 receptor accessory protein  1.90962 0.000221487
ICOS Inducible co-stimulator  1.903002 0.000880293
MYLIP Myosin regulatory light chain interacting protein  1.89332 8.32E-06
TGFBR3 Transforming growth factor, beta receptor III  1.8931 0.00121075
ZAP70 Zeta-chain (TCR) associated protein kinase 70 kDa  1.89061 0.000662326
CTSW Cathepsin W  1.88397 0.00129928
CEP78 Centrosomal protein 78 kDa  1.88364 0.000127057
ARL4C ADP-ribosylation factor-like 4C  1.8832 0.000160201
ARL4C ADP-ribosylation factor-like 4C  1.87226 0.000419378
KLRD1 Killer cell lectin-like receptor subfamily D, member 1  1.86593 0.00124982
PRKCQ Protein kinase C, theta  1.86552 0.00113571
NR4A1 Nuclear receptor subfamily 4, group A, member 1  1.86138 8.90E-05
SYTL2 Synaptotagmin-like 2  1.85889 0.00135142
ARL4C ADP-ribosylation factor-like 4C  1.85424 0.000286602
(Continued)
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TABLE 3 | Continued
Gene symbol Gene title Fold-change p-Value
AGAP1 ArfGAP with GTPase domain, ankyrin repeat and PH domain 1  1.80837 0.000287414
SH2D2A SH2 domain containing 2A  1.80828 0.000300214
KLRK1 Killer cell lectin-like receptor subfamily K, member 1  1.78448 0.00102739
RUNX3 Runt-related transcription factor 3  1.77892 0.00013984
KIR3DL3 Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3  1.70915 0.000885828
PER1 Period homolog 1 (Drosophila)  1.70146 0.000444082
CHD2 Chromodomain helicase DNA DNA-binding protein 2  1.70091 0.000257214
DTX3 Deltex homolog 3 (Drosophila)  1.70068 0.000829046
PRKCH Protein kinase C, eta  1.68436 0.00106358
FAM179A Family with sequence similarity 179, member A  1.68265 0.000135121
MGAT4A Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A  1.67906 0.000326335
GBP5 Guanylate binding protein 5  1.67871 0.000452814
MLC1 Megalencephalic leukoencephalopathy with subcortical cysts 1  1.66993 0.000433367
ANKRD36 Ankyrin repeat domain 36  1.63932 0.000866547
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  1.63898 0.000941657
SYNE2 Spectrin repeat containing, nuclear envelope 2  1.63663 1.19E-05
ID2 Inhibitor of DNA DNA-binding 2, dominant negative helix—loop—helix protein  1.60803 1.67E-06
KIF21A Kinesin family member 21A  1.60799 0.00136965
CTNNB1 Catenin (cadherin-associated protein), beta 1, 88 kDa  1.6076 4.09E-05
TSEN54 tRNA splicing endonuclease 54 homolog (S. cerevisiae)  1.60547 0.000604728
ZNF451 Zinc finger protein 451  1.60463 6.28E-06
TSPAN5 Tetraspanin 5  1.60208 0.00114212
RASGEF1A RasGEF domain family, member 1A  1.60149 0.000447691
TNIK TRAF2 and NCK interacting kinase  1.59894 2.50E-05
CBLB Cas-Br-M (murine) ecotropic retroviral transforming sequence b  1.5979 0.000320734
MLLT11 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocate  1.59317 0.000831119
TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31 kDa  1.5885 0.000321819
HNRNPL Heterogeneous nuclear ribonucleoprotein L  1.5871 3.77E-06
SESN2 Sestrin 2  1.57849 6.97E-05
LOC100130872 Hypothetical LOC100130872  1.56568 1.48E-05
SESN2 Sestrin 2  1.56417 0.00050745
CCL5 Chemokine (C—C motif) ligand 5  1.56409 0.000430274
PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)  1.56311 0.00143535
TFDP2 Transcription factor Dp-2 (E2F dimerization partner 2)  1.55293 0.000804861
PDE4B Phosphodiesterase 4B, cAMP-specific  1.55035 0.00085501
RBM14 RNA binding motif protein 14  1.54638 2.35E-05
FAM100B Family with sequence similarity 100, member B  1.53662 7.63E-05
PDE4D Phosphodiesterase 4D, cAMP-specific  1.53463 0.000469774
GRPEL1 GrpE-like 1, mitochondrial (E. coli)  1.53133 1.23E-05
ZNF507 Zinc finger protein 507  1.52977 0.000202111
NUP153 Nucleoporin 153 kDa  1.52758 0.000367042
FUS Fused in sarcoma  1.52544 0.0010451
PTTG1 Pituitary tumor-transforming 1  1.52511 0.000818797
WAC WW domain containing adaptor with coiled-coil  1.52328 0.000534293
EIF1 Eukaryotic translation initiation factor 1  1.52229 6.21E-06
TSEN54 tRNA splicing endonuclease 54 homolog (S. cerevisiae)  1.50904 0.000620767
MYLIP Myosin regulatory light chain interacting protein  1.50894 3.24E-05
CALU Calumenin  1.50768 0.000736822
EHD4 EH-domain containing 4  1.50216 0.000209267
ATP11B ATPase, class VI, type 11B 1.50127 0.000202173
FKBP15 FK506 binding protein 15, 133 kDa 1.50442 0.000270622
MOCS3 Molybdenum cofactor synthesis 3 1.5075 4.38E-06
FAM13A Family with sequence similarity 13, member A 1.50801 0.00135619
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.50849 2.59E-05
DACH1 Dachshund homolog 1 (Drosophila) 1.51638 0.000969487
HHEX Hematopoietically expressed homeobox 1.51675 6.21E-05
PDE7B Phosphodiesterase 7B 1.51869 2.37E-05
OBFC2A Oligonucleotide/oligosaccharide-binding fold containing 2A 1.52002 0.000343088
CR1 Complement component (3b/4b) receptor 1 (Knops blood group) 1.52311 9.05E-05
PHF23 PHD finger protein 23 1.53301 3.41E-06
ZNF780A Zinc finger protein 780A 1.53325 0.000505801
GPR27 G protein-coupled receptor 27 1.53487 0.0011538
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 1.53614 1.72E-05
ADPRH ADP-ribosylarginine hydrolase 1.53673 0.000301124
(Continued)
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TABLE 3 | Continued
Gene symbol Gene title Fold-change p-Value
TLR4 Toll-like receptor 4 1.54384 0.000155809
TLR10 Toll-like receptor 10 1.54391 0.000150659
SIRPB2 Signal-regulatory protein beta 2 1.55351 9.39E-05
FUBP1 Far upstream element (FUSE) binding protein 1 1.55437 3.43E-05
NLRC4 NLR family, CARD domain containing 4 1.5579 0.0010619
OBFC2A Oligonucleotide/oligosaccharide-binding fold containing 2A 1.55822 6.88E-05
TRPS1 Trichorhinophalangeal syndrome I 1.56073 0.00117806
CLIC4 Chloride intracellular channel 4 1.56137 0.00142631
ANKRD57 Ankyrin repeat domain 57 1.56891 0.000496592
FOSL2 FOS-like antigen 2 1.57091 0.00103799
FBXO30 F-box protein 30 1.57898 3.37E-05
S1PR3 Sphingosine-1-phosphate receptor 3 1.57953 0.000766403
MFAP3 Microfibrillar-associated protein 3 1.58049 8.30E-05
CPD Carboxypeptidase D 1.58561 0.000270503
RNF24 Ring finger protein 24 1.5887 0.000779404
PIGM Phosphatidylinositol glycan anchor biosynthesis, class M 1.58922 3.93E-06
SAP30L SAP30-like 1.599 3.48E-05
SERPINI2 Serpin peptidase inhibitor, clade I (pancpin), member 2 1.60236 0.000725023
BACH1 BTB and CNC homology 1, basic leucine zipper transcription factor 1 1.60519 5.89E-06
ZNF322B Zinc finger protein 322B 1.60589 0.000435523
ZEB2 Zinc finger E-box binding homeobox 2 1.61326 0.0010863
GPATCH2 G patch domain containing 2 1.61607 0.000829918
KCNE3 Potassium voltage-gated channel, Isk-related family, member 3 1.62682 0.000871206
ENTPD1 Ectonucleoside triphosphate diphosphohydrolase 1 1.62899 0.000688504
FAM114A1 Family with sequence similarity 114, member A1 1.63805 0.000957221
ZNF697 Zinc finger protein 697 1.63815 0.000362559
SIPA1L1 Signal-induced proliferation-associated 1 1-like 1 1.63837 0.000200843
MGST1 Microsomal glutathione S-transferase 1 1.63932 0.000155808
CENPBD1 CENPB DNA-binding domains containing 1 1.63975 0.000598446
LOC100505956 Hypothetical LOC100505956 1.6413 0.00103297
CTTNBP2NL CTTNBP2 N-terminal like 1.6428 0.00126079
CLLU1 Chronic lymphocytic leukemia up-regulated 1 1.65206 0.000787124
ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 1.66224 0.000130372
FAR2 Fatty acyl CoA reductase 2 1.68735 5.72E-05
DAPP1 Dual adaptor of phosphotyrosine and 3-phosphoinositides 1.68966 0.000609128
PLD1 Phospholipase D1, phosphatidylcholine-specific 1.69193 0.000517971
MGST1 Microsomal glutathione S-transferase 1 1.69246 0.00020858
MGST1 Microsomal glutathione S-transferase 1 1.69458 7.19E-06
DSC2 Desmocollin 2 1.69681 0.000254904
GPATCH2 G patch domain containing 2 1.70199 0.000112569
ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2 1.70328 0.000428429
FBN2 Fibrillin 2 1.721 0.000252441
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 1.72442 0.000706171
HP Haptoglobin 1.72582 0.000718758
FRAT2 Frequently rearranged in advanced T-cell lymphomas 2 1.72608 0.000190515
HHEX Hematopoietically expressed homeobox 1.7329 4.10E-06
P2RY13 Purinergic receptor P2Y, G-protein coupled, 13 1.73405 0.000133887
MGST1 Microsomal glutathione S-transferase 1 1.74784 7.56E-05
LOC100506828 Hypothetical LOC100506828 1.75228 7.44E-05
TFEC Transcription factor EC 1.75494 0.000135064
WLS Wntless homolog (Drosophila) 1.76165 0.000227731
FCGR1A///FCGR1C Fc fragment of IgG, high affinity Ia, receptor (CD64)///Fc fragment of IgG, high affinity 1.76282 0.00095328
SGMS2 Sphingomyelin synthase 2 1.76728 0.000618004
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 1.77021 3.21E-05
FPR2 Formyl peptide receptor 2 1.77041 8.98E-05
ADAM9 ADAM metallopeptidase domain 9 1.82176 2.72E-05
TMEM49 Transmembrane protein 49 1.8221 0.000516735
WSB1 WD repeat and SOCS box-containing 1 1.82444 0.000178707
NR3C1 Promoter 1B of the GR 1.83029221 0.00019027
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 1.83321 0.000299013
FPR2 Formyl peptide receptor 2 1.85476 0.000499535
EMP1 Epithelial membrane protein 1 1.8738 0.000128519
SPATA5L1 Spermatogenesis associated 5-like 1 1.87522 0.00102786
PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) 1.87895 0.000196578
(Continued)
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TABLE 3 | Continued
Gene symbol Gene title Fold-change p-Value
TLR1 Toll-like receptor 1 1.93858 2.14E-07
LOC203274 Hypothetical protein LOC203274 1.94801 5.09E-05
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 1.9776 5.93E-05
FBXO30 F-box protein 30 1.98992 0.000899931
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 1.99 0.000810192
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 1.99311 9.37E-06
STEAP4 STEAP family member 4 2.01298 0.000150426
IL8R1 Interleukin 8 receptor 1 2.03E+ 00 3.92893E-05
IL2 interleukin 2 2.03419987 3.10905E-06
FOLR3 Folate receptor 3 (gamma) 2.05781 0.00017189
FKBP15 FK506 binding protein 15, 133 kDa 2.094500914 4.30009E-05
SLITRK4 SLIT and NTRK-like family, member 4 2.16832 6.47E-05
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 2.18224 0.00016302
PTPRO Protein tyrosine phosphatase, receptor type, O 2.21369 0.000260765
FAM198B Family with sequence similarity 198, member B 2.22299 0.000661349
FKBP506 FKBP506 binding protein 2.223221099 1.90294E-06
IFNGR1 Interferon gamma receptor 1 2.51823 0.000195788
TLR7 Toll-like receptor 7 2.59205 0.00115974
RIN2 Ras and Rab interactor 2 2.62017 0.000313438
TLR8 Toll-like receptor 8 2.62471 0.00112645
TLR4 Toll-like receptor 4 2.66149 0.000182505
MIR21 MicroRNA 21 2.68409 0.000265287
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 2.83233 0.000146054
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 2.99062 7.43E-07
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 3.1238 0.000118651
The current study also found a significant increase in the
expression of 104 genes, with most being related to the regulation
of inflammatory activity (Table 5). Of these up-regulated genes,
the highest fold change is in pyruvate dehydrogenase kinase,
isozyme 4 (PDK4), with a 3.12-fold change in the improved sleep
group. This gene is of interest as it is located in the matrix
of the mitochondria. PDK4 reduces the conversion of pyruvate,
which is produced from the oxidation of glucose and amino acids,
to acetyl-CoA. It also contributes to the regulation of glucose
metabolism and has ramifications for overall health and morbid-
ity. PDK4 has not been previously linked to sleep disturbance or
mood. Here, we report that this gene increases expression in the
context of reduced expression of genes that influence inflamma-
tion and contribute significantly to metabolic risk. Exercise alters
the activity of PDK4, which relates to reductions in IL-6 activity,
suggesting that PDK4 is involved in metabolic processes that are
important to maintaining health (48). PDK4 is also implicated
in the maintenance of body weight during periods of fasting, as
it is required to maximize glucose metabolism; however, when
animals are exposed to high-caloric diets that are unrestricted,
PDK4 increases in expression (49). Therefore, PDK4 has complex
relations to comorbid conditions of type 2 diabetes, cardiovascular
disease, and other conditions that are common in military per-
sonnel and impact their morbidity. For these reasons, additional
studies are needed to determine how this gene relates to sleep and
mood, as well as morbidity risk in future studies.
In this study, we report two main gene-networks that are
implicated in sleep improvement. The first involves the key reg-
ulator CTNNβ1, a gene that relates to the activity of both IL-2
and TLR4, as well as ubiquitin genes (Figure 1). The CTNNβ1
is most often implicated in vulnerability to and recovery from
cancer (50–52); however, the role of this gene in sleep quality
has not yet been determined. This gene encodes for the β-catenin
protein, which regulates cell development and adhesion between
cells, in turn creating and preserving epithelial cell layers, which
is related to inflammatory gene activity. Activation of the Wnt
signaling pathway, which is a pertinent system for cell-to-cell
communications and which becomes activated during inflam-
matory responses, is essential in maintaining immune function
system balance between inflammatory and anti-inflammatory
activities. The result is increased concentrations of the protein that
is coded by CTNNβ1 gene, which is linked to both increases in
symptoms of depression and anxiety in clinical samples (53). Of
importance, we also report an increase in IL-2 gene expression,
which is a primary anti-inflammatory cytokine and is important
for regulating inflammatory cytokine activity including IL-1β,
IL-6, and TNF. Therefore, an increase in the expression of the
IL-2 gene in conjunction with other inflammatory regulators
suggests that regulatory gene networks are altered following sleep
restoration, and likely contribute to our previous finding of reduc-
tions in CRP following improved sleep (23). Thus, these gene-
expression findings together suggest that there is an alteration
in the activity of the acute-phase response, which is responsi-
ble for the initiation of CRP production. Although we did not
find that CRP significantly reduced in activity, our finding of
reductions in the activity of these precursor genes that are more
easily reduced in activity suggests that changes in CRP gene-
activity may require more time to observe. Although our findings
provide some key insights into the role of inflammation following
sleep change, much less is known about the long-term impact
of sleep disturbance on morbidity risks in military personnel
and veterans.
We also report that TLRs, and specifically TLR4 gene expres-
sion is increased in the improved sleep group, and is also a key
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TABLE 4 | Down-regulated gene expression (top 50).
Gene symbol Gene title Fold-change p-Value
CCL4 Chemokine (C–C motif) ligand 4  3.39 0.0004
EGR3 Early growth response 3  3.333 4.37E-05
IL1B Interleukin 1, beta  3.193 0.00054
TIGIT T cell immunoreceptor with Ig and ITIM domains  2.999 0.00012
CD96 CD96 molecule  2.999 0.00059
CCL3///CCL3L1///CCL3L3 Chemokine (C–C motif) ligand 3///chemokine (C–C motif) ligand 3-like 1///chemokine  2.998 1.32E-05
CCL5 Chemokine (C–C motif) ligand 5  2.966 0.00088
TNF Tumor necrosis factor  2.906 0.00054
DUSP1 Dual specificity phosphatase 1  2.897 1.73E-05
GATA3 GATA binding protein 3  2.889 0.00085
PTGS2 Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)  2.862 0.00012
BZRAP1 Benzodiazepine receptor (peripheral) associated protein 1  2.846 0.00043
KIR3DL1///KIR3DL2///LOC727787 Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1///k  2.796 0.00112
IL18R1 Interleukin 18 receptor 1  2.792 0.00131
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  2.776 0.00047
IFITM1 Interferon-induced transmembrane protein 1 (9–27)  2.676 0.0008
IL6 Interleukin 6 (interferon, beta 2)  2.666 0.00017
IFITM1 Interferon-induced transmembrane protein 1 (9–27)  2.591 0.0012
GLCCI1 Glucocorticoid induced transcript 1  2.579 0.00086
PER1 Period homolog 1 (Drosophila)  2.345 0.00017
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.313 0.00086
TARP TCR gamma alternate reading frame protein  2.243 0.00123683
TP53INP2 Tumor protein p53 inducible nuclear protein 2  2.232 2.18E-04
CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae)  2.223 0.00055
ZNF831 Zinc finger protein 831  2.212 0.00094
BCL10 B-cell CLL/lymphoma 10  2.196 1.92E-04
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.186 0.00138
TARP///TRGC2 TCR gamma alternate reading frame protein///T cell receptor gamma constant 2  2.172 0.00137
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor)  2.171 2.79E-05
IL13 Interleukin 13  2.1 0.00045
ZNF831 Zinc finger protein 831  2.074 0.001
GZMB Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)  2.073 0.00011
KLF12 Kruppel-like factor 12  2.067 0.00047
SPON2 Spondin 2, extracellular matrix protein  2.063 0.00056
MBNL2 Muscleblind-like 2 (Drosophila)  2.062 0.00015
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  2.05 0.00083
CRA Complement factor C4  2.048 7.09E-05
FCAR Fc fragment of IgA, receptor for  2.036 1.89E-04
NCL Nucleolin  2.031 4.39E-07
IFRD1 Interferon-related developmental regulator 1  2.025 7.16E-06
S1PR5 Sphingosine-1-phosphate receptor 5  2.00 0.00088
NAP1L5 Nucleosome assembly protein 1-like 5  1.983 0.00103
FGFBP2 Fibroblast growth factor binding protein 2  1.959 0.00098
TRD T cell receptor delta locus  1.953 0.00111
PYHIN1 Pyrin and HIN domain family, member 1  1.935 0.00099
GFI1 Growth factor independent 1 transcription repressor  1.932 0.00076
GZMM Granzyme M (lymphocyte met-ase 1)  1.931 0.00085
TRD T cell receptor delta locus  1.921 0.00112
TSC22D3 TSC22 domain family, member 3  1.911 2.28E-06
KLRB1 Killer cell lectin-like receptor subfamily B, member 1  1.91 0.00137
gene-network regulator of inflammatory activities. TLR4 recog-
nizes pathogen-associated molecular patterns that are expressed
by infectious agents, and mediate the production of cytokines
necessary for the development of effective immunity, thereby
regulating inflammatory cytokine activities following a stimulus.
TLR4 has been linked to repeated hypoxia events in a pre-clinical
model, suggesting that acute sleep deprivation may increase TLR
activity (54). Our findings of an increase in TLR4 following
improved sleep in conjunction with reduced activities of inflam-
matory cytokines suggests that the activities of TLR4 are impacted,
contributing to a restoration of inflammatory immune cell func-
tion. Since UBC is tightly related to TLR4 in our gene-network, it
may be that the protein-interaction properties of UBC that results
in lessened gene activity may contribute to this immune profile in
gene expression. It may also be that different molecular regulation
mechanisms, including DNAmethylation or other gene-silencing
processes, are occurring. Nonetheless, the presence of TLR4 in
this sample suggests it aided in the reduction of inflammation, as
well as interacting with other pathways within the improved sleep
group.
Frontiers in Psychiatry | www.frontiersin.org April 2015 | Volume 6 | Article 5910
Livingston et al. Improved sleep and gene expression
TABLE 5 | Up-regulated gene expression (top 50).
Gene symbol Gene title Fold-change p-Value
PDK4 Pyruvate dehydrogenase kinase, isozyme 4 3.1238 0.00012
CYP1B1 Cytochrome P450, family 1, subfamily B, polypeptide 1 2.83233 0.00015
MIR21 MicroRNA 21 2.68409 0.00027
TLR4 Toll-like receptor 4 2.66149 0.00018
TLR8 Toll-like receptor 8 2.62471 0.00113
RIN2 Ras and Rab interactor 2 2.62017 0.00031
TLR7 Toll-like receptor 7 2.59205 0.00116
IFNGR1 Interferon gamma receptor 1 2.51823 0.0002
FKBP506 FKBP506 binding protein 2.22322 1.90E-06
FAM198B Family with sequence similarity 198, member B 2.22299 0.00066
PTPRO Protein tyrosine phosphatase, receptor type, O 2.21369 0.00026
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 2.18224 0.00016
SLITRK4 SLIT and NTRK-like family, member 4 2.16832 6.47E-05
FKBP15 FK506 binding protein 15, 133 kDa 2.0945 4.30E-05
FOLR3 Folate receptor 3 (gamma) 2.05781 0.00017
IL2 Interleukin 2 2.0342 3.10E-06
IL8R1 Interleukin 8 receptor 1 2.03E+00 3.90E-05
STEAP4 STEAP family member 4 2.01298 0.00015
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 1.99 0.00081
FBXO30 F-box protein 30 1.98992 0.0009
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 1.9776 5.90E-05
LOC203274 Hypothetical protein LOC203274 1.94801 5.09E-05
TLR1 Toll-like receptor 1 1.93858 2.14E-07
PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) 1.87895 0.0002
SPATA5L1 Spermatogenesis associated 5-like 1 1.87522 0.00103
EMP1 Epithelial membrane protein 1 1.8738 0.00013
FPR2 Formyl peptide receptor 2 1.85476 0.0005
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 1.83321 0.0003
NR3C1 Promoter 1B of the GR 1.83029 0.00019
WSB1 WD repeat and SOCS box-containing 1 1.82444 0.00018
TMEM49 Transmembrane protein 49 1.8221 0.00052
ADAM9 ADAM metallopeptidase domain 9 1.82176 2.72E-05
FPR2 Formyl peptide receptor 2 1.77041 8.98E-05
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 1.77021 3.21E-05
SGMS2 Sphingomyelin synthase 2 1.76728 0.00062
FCGR1A///FCGR1C Fc fragment of IgG, high affinity Ia, receptor (CD64)///Fc fragment of IgG, high affinity 1.76282 0.00095
WLS Wntless homolog (Drosophila) 1.76165 0.00023
TFEC Transcription factor EC 1.75494 0.00014
LOC100506828 Hypothetical LOC100506828 1.75228 7.44E-05
MGST1 Microsomal glutathione S-transferase 1 1.74784 7.56E-05
P2RY13 Purinergic receptor P2Y, G-protein coupled, 13 1.73405 0.00013
HHEX Hematopoietically expressed homeobox 1.7329 4.10E-06
FRAT2 Frequently rearranged in advanced T-cell lymphomas 2 1.72608 0.00019
HP Haptoglobin 1.72582 0.00072
FCGR1B Fc fragment of IgG, high affinity Ib, receptor (CD64) 1.72442 0.00071
FBN2 Fibrillin 2 1.721 0.00025
ST6GALNAC3 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2 1.70328 0.00043
GPATCH2 G patch domain containing 2 1.70199 0.00011
DSC2 Desmocollin 2 1.69681 0.00025
MGST1 Microsomal glutathione S-transferase 1 1.69458 7.19E-06
Our findings also implicated the protein UBC pathway in gene
expression following improved sleep (Figure 2). Protein UBC
is required for the removal of oxidized or misfolded proteins
that are a consequence of neuronal activity that occurs during
waking hours; it also alters the location of the protein in the
cell or prevents protein interactions. In pre-clinical models, sub-
stantial sleep deprivation results in an accumulation of these bi-
products within neurons, and subsequent neuronal damage (55).
Accumulation of over-oxidized proteins is linked to cognitive
impairments in insomnia patients (56). Therefore, there is an
important role for ubiquitin in sleep regulation, which has been
recently described in pre-clinical models including Drosophila,
linking a knockdown of the E3 ubiquitin ligase Cul3 to sleep
disruption (57). Reductions in the activity of E3 ubiquitin lig-
ase Cul3 in neurons resulted in the insomniac phenotype (55).
In mice with a spontaneous deletion in the ubiquitin carboxyl-
terminal hydrolase L1 gene, there was a lower number of orexinA-
immunoreactive neurons in the lateral hypothalamus and greater
disruption in circadian rhythm compared to wild-type mice (58).
Thus, our findings, within the context of previous studies, suggest
that UBC genes are key mediators of sleep-related gene-activity
changes.
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Our findings have clinical relevance, as previous studies report
that insomnia tends to precede depression and PTSD and that
treatment of sleep disturbances decreases disease severity (59).
TABLE 6 | IPA network scores.
Networks Score
1 29
2 14
3 14
4 14
5 13
6 14
This table lists the scores of the six networks (Figures 1 and 2; Figures S1–S4 in
Supplementary Material) as reported by ingenuity pathway analysis (IPA). Following the
compilation of networks, based on the interconnectivity of each gene, IPA finalizes the
report by ranking each network based on a calculation of p-scores [p-score= log10(p-
value)]. This score accounts for the number of genes versus the size of the network to
estimate how valid this network is to the original list of genes. This allows for the networks
to be prioritized as seen in Table 6, where a score above 20 is seen as more significant.
Second, because of the stigma associated with mental illness,
military personnel are more likely to seek treatment for sleep
disturbances than for PTSD (14). Treatment for depression and
PTSD symptoms results in substantial financial cost that may be
mitigated by providing sleep interventions. In support of this,
a comprehensive study undertaken by the RAND corporation
estimates that treatment for either major depression or PTSD
costs between $5,000 and $15,000 for each military personnel
treated over 1 year (60). Lastly, our finding that even short-term
improvement in sleep has a significant impact on inflammatory
gene-activity, as well as reductions in depression symptoms, sug-
gests that early assessment and treatment for insomnia following
deployment is warranted, especially in military personnel with
mood declines.
While our study has strengths, including a validated sleep
measure, evaluation of comorbid symptoms, and a longitudinal
design, there are some notable limitations. These include a rela-
tively small sample of military personnel recruited from the same
treatment facility. In addition, our sample primarily consisted of
FIGURE 1 | This network shows genes related to cellular
development and connective tissue. Generated molecular network
based on differential expression in the improved sleep group from baseline
to follow-up using ingenuity knowledge database. Coloring is based on the
expression values of the genes (fold changes shown): down-regulation in
green and up-regulation in red. Genes with no coloring are added from
ingenuity knowledge database. Direct and indirect relationships are shown
by solid and dashed lines, respectively. The arrow indicates specific
directionality of interactions. Genes with an asterisk indicate that multiple
identifiers (probesets) map to the gene in the molecular network. Reprinted
with permission from QIAGEN’s Ingenuity® Pathway Analysis (IPA®)
(http://www.ingenuity.com/).
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FIGURE 2 | This network shows genes related to developmental disorders, as reported by IPA. Reprinted with permission from QIAGEN’s Ingenuity®
Pathway Analysis (IPA®) (http://www.ingenuity.com/).
male participants and therefore cannot be generalized to women.
Although we used validated questionnaires to determine PTSD
and depression symptoms, these instruments did not provide a
definitive clinical diagnosis. Lastly, other variations such as pre-
scribed medications used by patients prior to the study and dose
of treatment, including the number of treatment sessions attended
and other interventional methods could have further impact on
gene expression; however, the aim of this study is to focus on
symptom and gene-expression changes, not to validate a standard
of care treatment. In the future, a larger sample size and better
estimate of treatment adherence and fidelity among participants
are needed to confirm these findings.
Our novel findings suggest improved sleep quality has a biolog-
ical correlate as well as a correlationwith psychological symptoms.
Less is known regarding the long-term impact of sleep distur-
bance onmorbidity risks inmilitary personnel and veterans; how-
ever, our findings suggest that improving sleep quality reduces
inflammatory risks and psychiatric symptom severity. Therefore,
our findings provide fundamental insights related to the connec-
tions between sleep improvement and gene expression, including
inflammatory gene-activity, whichmay be used to reducemorbid-
ity risks in military personnel following deployment. Improving
assessment and treatment of sleep disturbance in this at-risk group
may provide a novel health promotion opportunity.
Supplementary Material
The SupplementaryMaterial for this article can be found online at
http://journal.frontiersin.org/article/10.3389/fpsyt.2015.00059/
abstract
Figure S1 | This network shows genes related to cell-mediated immune
responses, as reported by IPA. Reprinted with permission from QIAGEN’s
Ingenuity® Pathway Analysis (IPA®) (http://www.ingenuity.com/).
Figure S2 | This network shows genes related to connective tissue disor-
ders, as reported by IPA. Reprinted with permission from QIAGEN’s Ingenuity®
Pathway Analysis (IPA®) (http://www.ingenuity.com/).
Figure S3 | This network shows genes related to cellular function andmain-
tenance and cellular development, as reported by IPA. Reprinted with per-
mission from QIAGEN’s Ingenuity® Pathway Analysis (IPA®) (http://www.ingenuity.
com/).
Figure S4 | This network shows genes related to organismal injury and
abnormalities, as reported by IPA. Reprinted with permission from QIAGEN’s
Ingenuity® Pathway Analysis (IPA®) (http://www.ingenuity.com/).
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